Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements to be performed by additional healthcare professionals, including physician assistants and medical assistants, rather than being restricted solely to dermatologists. While a dermatologist must still initiate the test, we believe this expansion improves workflow flexibility, reduces operational bottlenecks, and supports broader clinical integration.
LÄS MER
